Tsung-Che Wu, Medical oncologist at NTUH in Taiwan, shared a post on X:
“Veritac-2: Vepdegestrant (PROTAC ER degrader) vs fulvestrant in 2L breast cancer.
positive for one of the primary endpoint: PFS in ESR1mt but not in ITT
– Milestone for drug development: the first positive phase 3 study of PROTAC for solid tumor,
– ESR1mt is a crucial marker for ER depndency at 2L and beyond,
– Interesting to compare the data and biomarkers vs trials of oral SERD.”
VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer